Skip to main content

Table 2 Association between PTH slope/residuals/mean and mortality, by level of adjustment

From: Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS)

Exposure

N (%)

Model 1

Model 2

Model 3

Model 3a

PTH slope (% change per month)

 Decreased > 15%

2189 (8%)

1.09 (0.97–1.22)

1.08 (0.96–1.21)

1.10 (0.98–1.25)

1.13 (1.00–1.28)

 Decreased 5–15%

5479 (20%)

1.12 (1.03–1.21)

1.05 (0.97–1.14)

1.06 (0.98–1.15)

1.07 (0.98–1.16)

 No change ±5%

10,776 (40%)

1 (Ref.)

1 (Ref.)

1 (Ref.)

1 (Ref.)

 Increased 5–15%

5750 (21%)

1.05 (0.97–1.13)

1.04 (0.97–1.13)

1.05 (0.97–1.13)

1.03 (0.96–1.12)

 Increased > 15%

2594 (10%)

1.07 (0.96–1.19)

1.06 (0.95–1.18)

1.08 (0.97–1.20)

1.04 (0.93–1.16)

PTH mean squared residuals

  < 0.01

2967 (11%)

0.98 (0.89–1.09)

1.01 (0.91–1.13)

1.01 (0.90–1.12)

1.01 (0.90–1.13)

 0.01–0.05

6205 (23%)

0.93 (0.86–1.01)

0.94 (0.87–1.02)

0.93 (0.86–1.01)

0.94 (0.86–1.02)

 0.05–0.20

9481 (35%)

1 (Ref.)

1 (Ref.)

1 (Ref.)

1 (Ref.)

 0.20–0.50

5043 (19%)

1.02 (0.94–1.11)

0.99 (0.91–1.08)

1.00 (0.92–1.09)

1.00 (0.92–1.09)

  > 0.50

3092 (12%)

0.95 (0.86–1.05)

0.97 (0.88–1.08)

0.98 (0.89–1.09)

0.99 (0.89–1.11)

PTH geometric mean (pg/mL)

  < 100

2975 (11%)

1.28 (1.16–1.41)

1.01 (0.91–1.12)

1.00 (0.90–1.11)

0.99 (0.89–1.11)

 100–199

6395 (24%)

1.09 (1.01–1.18)

0.93 (0.86–1.00)

0.92 (0.85–1.00)

0.94 (0.87–1.02)

 200–399

10,887 (41%)

1 (Ref.)

1 (Ref.)

1 (Ref.)

1 (Ref.)

 400–599

3666 (14%)

0.92 (0.83–1.01)

1.10 (1.00–1.22)

1.11 (1.01–1.22)

1.05 (0.95–1.17)

  ≥ 600

2865 (11%)

0.90 (0.81–1.00)

1.33 (1.18–1.50)

1.35 (1.20–1.52)

1.19 (1.04–1.35)

  1. HR (95% CI) of all-cause mortality for each exposure displayed
  2. Model 1: Stratified by phase, country, US-black race
  3. Model 2: Model 1 + adjusted for age, sex, vintage, catheter use, 13 comorbidities, mean values of BMI, nPCR, Hgb, creatinine, albumin over 9-month run-in period
  4. Model 3: Model 2 + simultaneous adjustment for all 3 exposures (PTH slope/residuals/mean)
  5. Model 3a: Model 3 + adjusted for potential mediators: prescription of phosphate binders, cinacalcet, IV vitamin D, and oral vitamin D, P mean, (P mean)^2, P slope, Ca mean, and Ca slope over 9-month run-in period